Sensitization of Gram-negative bacteria to rifampin and OAK combinations

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Jammal, Joanna ^a   Zaknoon, Fadia ^a   Kaneti, Galoz ^a   Goldberg, Keren ^a   Mor, Amram ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; OLIGOPEPTIDE; RIFAMPICIN;

ANIMAL; DRUG EFFECTS; DRUG POTENTIATION; GRAM NEGATIVE BACTERIUM; GRAM-POSITIVE BACTERIAL INFECTIONS; INSTITUTE FOR CANCER RESEARCH MOUSE; KLEBSIELLA; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOUSE; SYNTHESIS; VETERINARY;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG SYNERGISM; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; KLEBSIELLA; MALE; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; OLIGOPEPTIDES; RIFAMPIN;

EID: 84925070956     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep09216     Document Type: Article

References (46)

1. Torres, J. A., Villegas, M. V. & Quinn, J. P. Current concepts in antibiotic-resistant gram-negative bacteria. Expert Rev. Anti Infect. Ther. 5, 833-843 (2007).
2. Freire-Moran, L. et al. Critical shortage of new antibiotics in development against multidrug-resistant bacteria-Time to react is now. Drug Resist. Updat. 14, 118-124 (2011).
3. Butler, M. S., Blaskovich, M. A. & Cooper, M. A. Antibiotics in the clinical pipeline in 2013. J. Antibiot. 66, 571-591 (2013).
4. Kinch, M. S., Patridge, E., Plummer, M. & Hoyer, D. An analysis of FDA-approved drugs for infectious disease: antibacterial agents. Drug Discov. Today 19, 1283-1287 (2014).
5. Radzishevsky, I. S. et al. Improved antimicrobial peptides based on acyl-lysine oligomers. Nat. biotechnol. 25, 657-659 (2007).
6. Radzishevsky, I. S. et al. Structure-activity relationships of antibacterial acyl-lysine oligomers. Chem. Biol. 15, 354-362 (2008).
7. Livne, L. et al. Design and characterization of a broad -spectrum bactericidal acyl-lysyl oligomer. Chem. Biol. 16, 1250-1258 (2009).
8. Epand, R. F., Sarig, H., Mor, A. & Epand, R. M. Cell-wall interactions and the selective bacteriostatic activity of a miniature oligo-acyl-lysyl. Biophys. J. 97, 2250-2257 (2009).
9. Sarig, H. et al. A miniature mimic of host defense peptides with systemic antibacterial efficacy. FASEB J. 24, 1904-1913 (2010).
10. Goldberg, K. et al. Sensitization of gram-negative bacteria by targeting the membrane potential. FASEB J. 27, 3818-3826 (2013).
11. Kaneti, G., Sarig, H., Marjieh, I., Fadia, Z. & Mor, A. Simultaneous breakdown of multiple antibiotic resistance mechanisms in S. aureus. FASEB J. 27, 4834-4843 (2013).
12. Leive, L. The barrier function of the gram-negative envelope. Ann. N. Y. Acad. Sci. 235, 109-129 (1974).
13. Hancock, R. E. W. Alterations in outer membrane permeability. Annu. Rev. Microbiol. 38, 237-264 (1984).
14. Cirioni, O. et al. Protective effects of the combination of alpha-helical antimicrobial peptides and rifampicin in three rat models of Pseudomonas aeruginosa infection. J. Antimicrob. Chemother. 62, 1332-1338 (2008).
15. Vaara, M. Novel derivatives of polymyxins. J. Antimicrob Chemother. 68, 1213-1219 (2013).
16. Khara, J. S. et al. Anti-mycobacterial activities of synthetic cationic alpha-helical peptides and their synergism with rifampicin. Biomaterials 35, 2032-2038 (2014).
17. Petrosillo, N., Ioannidou, E. & Falagas, M. E. Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin. Microbiol. Infect. 14, 816-827 (2008).
18. Vaara, M. Agents That Increase the Permeability of the Outer-Membrane. Microbiol. Rev. 56, 395-411 (1992).
19. Jin, D. J. & Gross, C. A. Mapping and Sequencing of Mutations in the Escherichia- Coli Rpob Gene That Lead to Rifampicin Resistance. J. Mol. Biol. 202, 45-58 (1988).
20. Campbell, E. A. et al. Structural mechanism for rifampicin inhibition of bacterial rna polymerase. Cell 104, 901-912 (2001).
21. Hui, J., Gordon, N. & Kajioka, R. Permeability Barrier to Rifampin in Mycobacteria. Antimicrob. Agents Chemother. 11, 773-779 (1977).
22. Brennan, P. J. & Nikaido, H. The envelope of mycobacteria. Annu. Rev. Biochem. 64, 29-63 (1995).
23. Sarig, H., Rotem, S., Ziserman, L., Danino, D. & Mor, A. Impact of self-assembly properties on antibacterial activity of short acyl-lysine oligomers. Antimicrob. Agents Chemother. 52, 4308-4314 (2008).
24. Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model. Am. J. Respir. Crit. Care Med. 187, 1127-1134 (2013).
25. Lyons, M. A., Reisfeld, B., Yang, R. S. & Lenaerts, A. J. A physiologically based pharmacokinetic model of rifampin in mice. Antimicrob. Agents Chemother. 57, 1763-1771 (2013).
26. Westerhoff, H. V., Juretic, D., Hendler, R. W. & Zasloff, M. Magainins and the disruption of membrane-linked free-energy transduction. Proc. Natl. Acad. Sci. U.S.A. 86, 6597-6601 (1989).
27. Lehrer, R. I., Barton, A. & Ganz, T. Concurrent assessment of inner and outer membrane permeabilization and bacteriolysis in E. coli by multiple-wavelength spectrophotometry. J. Immunol. Methods 108, 153-158 (1988).
28. Storm, D. R., Rosenthal, K. S. & Swanson, P. E. Polymyxin and related peptide antibiotics. Annu. Rev. Biochem. 46, 723-763 (1977).
29. Daugelavicius, R., Bakiene, E. & Bamford, D. H. Stages of polymyxin B interaction with the Escherichia coli cell envelope. Antimicrob. Agents Chemother. 44, 2969-2978 (2000).
30. Velkov, T., Thompson, P. E., Nation, R. L. & Li, J. Structure - activity relationships of polymyxin antibiotics. J. Med. Chem. 53, 1898-1916 (2010).
31. Moore, R. A., Bates, N. C. & Hancock, R. E. W. Interaction of Polycationic Antibiotics with Pseudomonas-Aeruginosa Lipopolysaccharide and Lipid-a Studied by Using Dansyl-Polymyxin. Antimicrob. Agents Chemother. 29, 496-500 (1986).
32. Ellard, G. A. et al. The Bioavailability of Isoniazid, Rifampin, and Pyrazinamide in 2 Commercially Available Combined Formulations Designed for Use in the Short-Course Treatment of Tuberculosis. Am. Rev. Respir. Dis. 133, 1076-1080 (1986).
33. Gordin, F. et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. JAMA 283, 1445-1450 (2000).
34. Eliopoulos, G. M. & Eliopoulos, C. T. Antibiotic combinations: should they be tested? Clin. Microbiol. Rev. 1, 139-156 (1988).
35. Tamma, P. D., Cosgrove, S. E. & Maragakis, L. L. Combination therapy for treatment of infections with gram-negative bacteria. Clin. Microbiol. Rev. 25, 450-470 (2012).
36. Nikaido, H. Molecular Basis of Bacterial Outer Membrane Permeability Revisited. Microbiol. Mol. Biol. Rev. 67, 593-656 (2003).
37. Vaara, M. et al. Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. Antimicrob. Agents Chemother. 52, 3229-3236 (2008).
38. Vaara, M., Siikanen, O., Apajalahti, J., Frimodt-Moller, N. & Vaara, T. Susceptibility of carbapenemase-producing strains of Klebsiella pneumoniae and Escherichia coli to the direct antibacterial activity of NAB739 and to the synergistic activity of NAB7061 with rifampicin and clarithromycin. J. Antimicrob. Chemother. 65, 942-945 (2010).
39. Kalita, A., Verma, I. & Khuller, G. K. Role of human neutrophil peptide-1 as a possible adjunct to antituberculosis chemotherapy. J. Infect. Dis. 190, 1476-1480 (2004).
40. Scott, R. W., DeGrado, W. F. & Tew, G. N. De novo designed synthetic mimics of antimicrobial peptides. Curr. Opin. Biotechnol. 19, 620-627 (2008).
41. Rotem, S. & Mor, A. Antimicrobial peptide mimics for improved therapeutic properties. Biochim. Biophys. Acta 1788, 1582-1592 (2009).
42. Vlieghe, P., Lisowski, V., Martinez, J. & Khrestchatisky, M. Synthetic therapeutic peptides: science and market. Drug Discov. Today 15, 40-56 (2010).
43. Marr, A. K., Gooderham, W. J. & Hancock, R. E. W. Antibacterial peptides for therapeutic use: obstacles and realistic outlook. Curr. Opin. Pharmacol. 6, 468-472 (2006).
44. Schuerholz, T., Brandenburg, K. & Marx, G. Antimicrobial peptides and their potential application in inflammation and sepsis. Crit. Care 16, 207 (2012).
45. Fields, G. B. & Noble, R. L. Solid-Phase Peptide-Synthesis Utilizing 9-Fluorenylmethoxycarbonyl Amino-Acids. Int. J. Pept. Prot. Res. 35, 161-214 (1990).
46. Zhang, L., Dhillon, P., Yan, H., Farmer, S. & Hancock, R. E. Interactions of bacterial cationic peptide antibiotics with outer and cytoplasmic membranes of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 44, 3317-3321 (2000).